Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE:300497)

China · Delayed Price · Currency is CNY

20.02

+0.04 (0.20%)

Sep 11, 2026, 3:04 PM CST

Market Cap	10.76B +93.4%
Revenue (ttm)	1.56B +54.3%
Net Income	128.83M
EPS	0.27
Shares Out	538.65M
PE Ratio	73.33
Forward PE	15.49
Dividend	0.10 (0.54%)
Ex-Dividend Date	Aug 24, 2026

Volume	35,030,240
Open	19.98
Previous Close	19.98
Day's Range	19.63 - 20.22
52-Week Range	9.40 - 24.18
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About SHE:300497

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers β-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersible tablets to treat rickettsial diseases, mycoplasmal and chlamydial infections, relapsing fever, brucellosis, cholera, tularemia, plague, and chancro... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 1,663

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 300497

Full Company Profile

Financial Performance

In 2025, SHE:300497's revenue was 1.18 billion, an increase of 0.61% compared to the previous year's 1.18 billion. Losses were -55.03 million, -79.78% less than in 2024.

Financial Statements